Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11627)	11/24/1997 9:28:00 AM
From: Arthur Radley	Respond to of 32384

Morning Henry, Doesn't look good at the open for the general market. Indication on LGND is positive but worry about the overall mood today and anticipation of Japanese market tomorrow. Maybe the ALRI deal will give LGND an upward bias today(:>)

To: Henry Niman who wrote (11627)	11/24/1997 10:24:00 AM
From: Russian Bear	Read Replies (1) \| Respond to of 32384

Henry, The electronic version of today's press release is out now: biz.yahoo.com Best regards, RB

To: Henry Niman who wrote (11627)	11/24/1997 11:38:00 AM
From: JOEBT1	Read Replies (1) \| Respond to of 32384

LGND has stated that their objective is to be profitable in '99. The estimated numbers (my guesses) for '99 are as follows: Revenue from collaborative R&D could reach 50m (40m for '97); Costs and expenses may rise to 100m (80m for '97); Net loss before new drug revenues and MFG. expenses would be 50m(43 for '97). New drug revenues for profitability would have to be 75 to 100m (MFG costs would come out of drug revenues). My view of approved drugs in '97 would include Panretin gel and oral for KS; Targretin gel and oral for CTCL; Droloxifene; and possibly the selected LLY drug. All the above is an "amateur" analysis and shouldn't be relied on for investments decisions. I would be interested in your views, Henry (and others) on the above, particularly the approved LGND drugs on the market in '99.